NCT04232722Unknown2 期
An Exploratory Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Sorafenib Combined With Realgar-Indigo Naturalis Formula (RIF) in in Treating Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Zhejiang University1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2020年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation
详细描述
Background: postoperative recurrence after liver transplantation is a global problem, and there is no standard treatment model for postoperative recurrence. Objective: to select patients diagnosed with hepatocellular carcinoma (HCC) after liver transplantation and unable to receive local treatment, and to give sorafenib combined with realgar-indigo naturalis formula until the disease progression or the patient die or is lost to follow-up. To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged 18-75 (inclusive), male or female;
- •recurrence of HCC after liver transplantation;
- •grade C according to the Barcelona liver cancer classification criteria (BCLC) or grade B not suitable for local treatment/progression of local treatment
- •according to RECIST1.1, there was at least one target lesion that could be stably evaluated, defined as: longest diameter of non-lymph node lesion ≥10mm, or shortest diameter of lymph node lesion ≥15mm; The intrahepatic lesions required enhanced arterial development
- •expected survival more than 12 weeks;
- •child-pugh score ≤7;
- •ECOG score 0-1;
- •if the subject is HBsAg positive or HBcAb positive, hbv-dna < 200 IU/ml should be satisfied. HBsAg positive subjects must receive antiviral therapy in accordance with the 2015 guidelines for the prevention and treatment of chronic hepatitis B.
- •subject should meet the following test results before screening and pretreatment (at baseline). If abnormal laboratory tests do not meet the following criteria, the subjects are allowed to re-examine within one week. If they still do not meet the criteria, the screening will be considered a failure: A. Blood routine (no blood transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) and other supportive treatments should be performed within 7 days before the test) : WBC ≥ 2.5×109/L; Platelet count (PLT) ≥60×109/L; Hemoglobin (Hb) ≥ 9.0g /dL; B. Blood biochemistry: serum albumin (Alb) ≥30 g/L; The clearance rate of endogenous creatinine was ≥50 mL/min (Cockcroft -Gault formula was used). Alanine aminotransferase (ALT) ≤5× upper limit of normal value (ULN); Aspartate aminotransferase (AST) ≤5×ULN; Alkaline phosphatase ≤5×ULN; Total bilirubin ≤2×ULN; C. Prothrombin time (PT) : prothrombin time extension ≤ 4 s;
- •women of child-bearing age must undergo a serum pregnancy test within the screening period and 14 days prior to the initiation of the study drug, with negative results, and be willing to use reliable methods of contraception during the test period; Male subjects whose partners are women of child-bearing age should be sterilized or agree to use reliable methods of contraception during the trial;
- •be able to understand and sign the informed consent.
排除标准
- •participate in other clinical trials or use other research drugs or devices within 4 weeks of the first treatment.
- •pregnant or breastfeeding women;
- •positive for human immunodeficiency virus (HIV) antibody, treponema pallidum antibody or hepatitis C virus (HCV-RNA) antibody;
- •any uncontrolled active infection, including but not limited to subjects with active tuberculosis;
- •previous or present hepatic encephalopathy;
- •the presence of clinically significant ascites is defined as the ascites that are positive on physical examination or that need to be controlled by intervention therapy (for example, puncture or drug therapy, etc.).
- •imaging results: the proportion of liver replaced by tumor was ≥50%, and the main portal vein tumor thrombus or tumor thrombus invaded mesenteric vein/inferior vena cava;
- •adverse reactions caused by previous treatment did not return to the standard term for adverse events (CTCAE) ≤1, except hair loss and other tolerable events judged by researchers;
- •subjects who currently have unstable or active ulcers, gastrointestinal bleeding, or intolerance to proton pump inhibitors;
研究组 & 干预措施
Sorafenib + arsenical
Experimental
After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
干预措施: Arsenicals (Drug)
结局指标
主要结局
ORR
时间窗: Through the study peirod, for 18 months
objective response rate
次要结局
- OS(Through the study peirod, for 18 months)
- Safty(Through the study peirod, for 18 months)
- DCR(Through the study peirod, for 18 months)
- PFS(Through the study peirod, for 18 months)
研究者
TingBo Liang
Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid TumorsRefractory MalignancyNCT00613145SCRI Development Innovations, LLC32
已完成
1 期
Drug Interaction Study of Sorafenib and Rapamycin in Advanced MalignanciesAdvanced Solid TumorNCT00449280University of Chicago34
已完成
1 期
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00134069National Cancer Institute (NCI)48
进行中（未招募）
2 期
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid CancerThyroid CancerNCT01141309Memorial Sloan Kettering Cancer Center41
已完成
1 期
Sorafenib Gastric Cancer Asian Phase I StudyGastric CancerNCT00663741Bayer13